NCT06295120 The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)
| NCT ID | NCT06295120 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Research Unit for General Practice in Aalborg |
| Condition | Community-acquired Pneumonia |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-11-13 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 600 participants in total. It began in 2023-11-13 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this randomised controlled trial is to identify the optimal treatment duration with phenoxymethylpenicillin for community-acquired pneumonia diagnosed in general practice. Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics. Consenting patients who meet all the eligibility criteria will be randomised (1:1:1:1:1) to either three, four, five, six or seven days of treatment with phenoxymethylpenicillin 1.2 MIE four times daily.
Eligibility Criteria
Inclusion Criteria: Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnoea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics. Exclusion Criteria: 1. Need for immediate hospitalisation at the time of diagnosis. 2. Known allergy to beta-lactam antibiotics. 3. Any coinfection necessitating antibiotic treatment. 4. Use of systemic antibiotics or antivirals within the last month. 5. Pre-existing lung disease (e.g., chronic obstructive pulmonary disease, bronchiectasis, asthma, lung cancer). 6. Known immunosuppression (i.e., long term treatment with corticosteroid, chemotherapy, or immune disorder). 7. Pregnant or lactating. 8. Patients not capable of consenting and/or patients deemed non-suitable for participation by the healthcare professional.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06295120 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Community-acquired Pneumonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06295120 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06295120 currently recruiting?
Yes, NCT06295120 is actively recruiting participants. Contact the research team at ejoha@dcm.aau.dk for enrollment information.
Where is the NCT06295120 trial being conducted?
This trial is being conducted at Gistrup, Denmark.
Who is sponsoring the NCT06295120 clinical trial?
NCT06295120 is sponsored by Research Unit for General Practice in Aalborg. The trial plans to enroll 600 participants.